Composition: Brinzolamide 1% w/v + Brimonidine Tartrate 0.2% w/v
Formulation: Eye Drops
Category: Anti-Glaucoma
Packaging: 5ML



Therapy/Class: Anti-Glaucoma
Mechanism of Action:
Brimonidine Tartrate: A highly selective alpha-2 adrenergic receptor agonist. It lowers intraocular pressure through a dual mechanism: actively suppressing aqueous humor production from the ciliary body and enhancing uveoscleral outflow pathways.
Brinzolamide: A specific, reversible, non-competitive inhibitor of carbonic anhydrase II (CA-II) in the ciliary epithelium. By slowing the formation of bicarbonate ions, it reduces sodium and fluid transport, directly inhibiting aqueous humor production.
Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma
Management of ocular hypertension
Note: This is an indicative Indication, please follow the doctors advise. Do not self medicate.
Instill 1 drop into the inferior conjunctival cul-de-sac of the affected eye(s) as prescribed by the physician. Dosing frequency should be adjusted according to clinical response and severity.
Note: This is an indicative dosage, please follow the doctors advise. Do not self medicate.
1. Katz LJ, et al. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma. Curr Med Res Opin. 2002;18(4):231-238.
2. Toris CB, et al. Aqueous humor dynamics in the aging human eye. Am J Ophthalmol. 1999;127(4):407-412.
1. Sall K, et al. Clinical efficacy of brinzolamide 1% vs dorzolamide 2% in primary open-angle glaucoma. Surv Ophthalmol. 2000;44(Suppl 2):S155-S162.
Warning: This information is only for the use of registered medical practitioners only.
Error: Contact form not found.
